Related Experiment Videos
The human and economic costs of undertreatment with statins
1Department of Medicine, Manchester Royal Infirmary, University of Manchester, UK.
Insights
Despite guidelines, underuse of statins for coronary heart disease (CHD) prevention impacts patient outcomes. Newer statins may improve efficacy and cost-effectiveness, warranting further clinical trials.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Coronary heart disease (CHD) guidelines recommend lipid-lowering therapy, primarily statins, based on LDL-C levels and risk factors.
- Statins are proven effective in reducing CHD mortality and morbidity.
- Despite recommendations, statin therapy is underutilized in clinical practice, with many patients not reaching target LDL-C levels.
Purpose of the Study:
- To highlight the underuse of lipid-lowering therapy in CHD prevention.
- To discuss reasons for underutilization, including physician/patient factors and economic perceptions.
- To evaluate the cost-effectiveness of statin therapy and explore the potential of newer statins.
Main Methods:
- Review of existing guidelines for CHD prevention and management.
- Analysis of clinical practice patterns regarding lipid-lowering therapy.
- Examination of health economic evaluations of statin therapy.
- Consideration of the potential benefits of newer, more efficacious statins.
Main Results:
- Significant underuse of statin therapy exists, even for secondary CHD prevention.
- Many patients on statins do not achieve their target low-density lipoprotein cholesterol (LDL-C) levels.
- Health economic evaluations support the cost-effectiveness of statins for both primary and secondary CHD prevention.
Conclusions:
- Underuse of statins negatively impacts patient outcomes, quality of life, and incurs societal economic costs.
- Physician and patient factors, alongside economic perceptions, contribute to therapy underutilization.
- Newer statins with enhanced LDL-C reduction may offer improved clinical outcomes and long-term cost-effectiveness, meriting further investigation.
Abstract:
Several guidelines for the prevention and management of coronary heart disease (CHD) have been published. These generally recommend lipid-lowering therapy in patients with and without established CHD on the basis of their low-density lipoprotein cholesterol (LDL-C) levels and, for cases without established CHD, their risk-factor profile. Statins are the preferred lipid-lowering agent for the prevention of CHD because of overwhelming clinical trial evidence that they can significantly reduce the occurrence of CHD mortality and morbidity. Despite the guidelines, only approximately one-third of eligible patients receive lipid-lowering therapy in clinical practice--even for secondary prevention of CHD--and many treated patients fail to achieve their target LDL-C levels. This underuse must affect patients' clinical outcome and quality of life and has economic consequences for society. Reasons for the underuse may include physicians' and patients' attitudes and knowledge, and the perceptions of physicians and healthcare purchasers about economic factors. Health economic evaluations have confirmed that secondary prevention with statins is cost-effective, and that primary prevention is also reasonably cost-effective, depending on the absolute CHD risks in targeted individuals. Newer statins with greater efficacy in reducing LDL-C levels may allow patients to reach target levels more quickly and without the need for dose titration, thus improving clinical outcomes and being more cost-effective in the long term. This proposition should be testedin future clinical trials.